Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy
Reid Shaw1, James J Yoon2, Hannah Johnston1
1Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.
Blood Advances
|February 19, 2025
Abstract
No abstract available in PubMed .


